Over the past week, the stock market has continued to decline. Leading the decline are biotechnology company stocks, which have fallen by 5-8%. You can receive signals for these company stocks by subscribing to our robots: Swing-trader-Downtrend-Protection-v-2-TA.
Notable Companies
Some of the most prominent companies in the Biotechnology industry include:
Industry Description
Biotechnology is a diverse field that involves genetic and protein engineering to develop medications and therapies for the treatment and prevention of various medical conditions. Additionally, the industry plays a crucial role in producing essential components for diagnostic purposes. It's a multi-billion-dollar industry with a strong focus on research and development to innovate cutting-edge healthcare solutions.
Discoveries in the biotechnology sector have the potential for substantial growth. However, these breakthroughs must undergo rigorous regulatory approval processes, often by the U.S. Food and Drug Administration (FDA), before they can be introduced to the market. Some well-known companies in this industry include Amgen Inc., Gilead Sciences, Inc., and Celgene Corporation.
Market Capitalization
The average market capitalization within the Biotechnology industry is approximately $2.2 billion. Companies in this sector exhibit a wide range of market capitalization, spanning from $402 million to $410.2 billion. Notably, NVO holds the highest valuation in this group at $410.2 billion, while the lowest valued company is PNEXF at $402 million.
High and Low Price Notable News
Price fluctuations in the Biotechnology industry are quite dynamic. The average weekly price movement across all stocks in this sector was -3.83%. Over a monthly period, the average price growth was more positive at 22.16%, and for a quarter, it further increased to 34.16%. Among individual stocks, RNAZ experienced remarkable price growth at 335.08%, while SEEL faced a significant decline of -80.84%.
Some recent price highlights include:
Volume
The trading volume in the Biotechnology Industry is subject to fluctuations. On average, there was a weekly volume growth of 62.71% across all stocks in the industry. Over a month, the average volume growth was 135.64%, and for a quarter, it was 125.83%.
Some notable volume events include:
Fundamental Analysis Ratings
Fundamental analysis ratings help assess the overall health and performance of companies in the industry. These ratings are on a scale from 1 (best) to 100 (worst) and are as follows:
MRNA sees MACD Histogram crosses below signal line on September 19, 2023. This is a bearish signal, with an 85% chance of a downward move.
ALNY: The 10-day Moving Average crossed above the 50-day moving average on September 01, 2023, suggesting a 78% chance of an upward trend continuation.
BGNE: Broke above its upper Bollinger Band on August 29, 2023, indicating a 90% chance of a subsequent drop.
LEGN moved below its 50-day Moving Average on September 05, 2023, signaling a 90% chance of a continued downward trend.
RPRX: The Aroon Indicator entered a downward trend on September 15, 2023, with a 73% chance of a stock decline.
ROIV: The 10-day RSI Indicator moved out of overbought territory on September 11, 2023, implying a 78% chance of a downward trend.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
The 10-day RSI Indicator for MRNA moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 26 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In 74 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
MRNA moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 217 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 108 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.010) is normal, around the industry mean (3.596). P/E Ratio (-31.853) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of transformative medicines for patients
Industry Biotechnology